ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma

Yang, Yongyu; Gao, Lei; Chen, Junzhang; Xiao, Wang; Liu, Ruoqi; Kan, Heping*南方医科大学
Bioengineered2022-4-1DOI: 10.1080/21655979.2022.2057896
5被引4阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is an aggressive malignancy. Previous studies have found that lamin B1 (LMNB1) contributes to the development of human cancers. However, the biological functions and prognostic values of LMNB1 in HCC have not been adequately elucidated. In our present research, the expression pattern of LMNB1 was analyzed. The prognostic values of LMNB1 were evaluated by Kaplan-Meier survival analysis and Cox proportional hazards regression analysis. The effects of LMNB1 on HCC progression were assessed by Cell Counting Kit-8 (CCK-8), colony formation, wound healing, Transwell and in vivo xenograft assays. The mechanisms of LMNB1 in HCC progression were elucidated by gene set enrichment analysis (GSEA) and loss-of-function assays. Besides, a nomogram for predicting overall survival (OS) was constructed. The results demonstrated that LMNB1 was overexpressed in HCC and that increased LMNB1 expression predicted a dismal prognosis. Further experiments showed that LMNB1 facilitated cell proliferation and metastasis in HCC. Functional enrichment analysis revealed that LMNB1 modulated metastasis-associated biological functions such as focal adhesion, extracellular matrix, cell junctions and cell adhesion. Mechanistically, we revealed that LMNB1 promoted HCC progression by regulating the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Moreover, incorporating LMNB1, Ki67 and Barcelona Clinic Liver Cancer (BCLC) stage into a nomogram showed better predictive accuracy than the Tumor-Node-Metastasis (TNM) stage and BCLC stage. In conclusion, LMNB1 may serve as an effective therapeutic target as well as a reliable prognostic biomarker for HCC.

学科与关键词

关键词
Hepatocellular carcinomaLMNB1therapeutic targetprognostic biomarkernomogram
相关
加载中…
  • A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
    Yang, Yongyu; Xiao, Wang; Liu, Ruoqi; Gao, Lei; Chen, Junzhang; Kan, Heping*Journal of Immunology Research, 2022, 2022: 4983532.被引 2
  • LMO1 Promotes the Development of Hepatocellular Carcinoma by Regulation of bcl-2 and bax
    Zhang, Jianfeng; Peng, Bojian; Li, Zhuowen; Zhang, Yuan; Zhang, Yongjun; Lu, Xiushan; Cao, Yanwen; Dai, Zijun; Xiong, Chuanyin*Journal of Biomaterials and Tissue Engineering, 2023, 13(3): 475-481.
  • MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma
    Xie Chan; Wu Jueheng; Yun Jingping; Lai Jiaming; Yuan Yunfei; Gao Zhiliang; Li Mengfeng; Li Jun; Song Libing*PLoS ONE, 2013, 8(5): e64235.被引 17
查看全部 →

发表信息

论文状态
公开发表
期刊
Bioengineered
发表日期
2022-04-01
卷期
第 13 卷, 第 4 期
页码
9211-9231
DOI
10.1080/21655979.2022.2057896
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [NSF-GP 2016A030313555]

作者

  • Y

    Yang, Yongyu (第一作者)

    southern med univ

  • G

    Gao, Lei

    southern med univ

查看全部 6 位作者收起作者
  • C

    Chen, Junzhang

    southern med univ

  • X

    Xiao, Wang

    southern med univ

  • L

    Liu, Ruoqi

    southern med univ

  • K

    Kan, Heping (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417